Recurrent inhibition of mitochondrial complex III induces chronic pulmonary vasoconstriction and glycolytic switch in the rat lung
Affiliation
Univ Arizona, Dept Med, Div EndocrinolUniv Arizona, Dept Med
Issue Date
2018-04-23Keywords
Pulmonary hypertensionGlycolytic switch
Mitochondrial complexes
Protein nitration
Metabolomics
Metadata
Show full item recordPublisher
BIOMED CENTRAL LTDCitation
Rafikova, O., Srivastava, A., Desai, A. A., Rafikov, R., & Tofovic, S. P. (2018). Recurrent inhibition of mitochondrial complex III induces chronic pulmonary vasoconstriction and glycolytic switch in the rat lung. Respiratory research, 19(1), 69.Journal
RESPIRATORY RESEARCHRights
© The Author(s). 2018. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Background: Pulmonary arterial hypertension (PAH) is a fatal disease; however, the mechanisms directly involved in triggering and the progression of PAH are not clear. Based on previous studies that demonstrated a possible role of mitochondrial dysfunction in the pathogenesis of PAH, we investigated the effects of chronic inhibition of mitochondrial function in vivo in healthy rodents. Methods: Right ventricle systolic pressure (RVSP) was measured in female rats at baseline and up to 24 days after inhibition of mitochondrial respiratory Complex III, induced by Antimycin A (AA, 035 mg/kg, given three times starting at baseline and then days 3 and 6 as a bolus injection into the right atrial chamber). Results: Rodents exposed to AA demonstrated sustained increases in RVSP from days 6 through 24. AA-exposed rodents also possessed a progressive increase in RV end-diastolic pressure but not RV hypertrophy, which may be attributed to either early stages of PAH development or to reduced RV contractility due to inhibition of myocardial respiration. Protein nitration levels in plasma were positively correlated with PAH development in AA-treated rats. This finding was strongly supported by results obtained from PAH humans where plasma protein nitration levels were correlated with markers of PAH severity in female but not male PAH patients. Based on previously reported associations between increased nitric oxide production levels with female gender, we speculate that in females with PAH mitochondrial dysfunction may represent a more deleterious form, in part, due to an increased nitrosative stress development. Indeed, the histological analysis of AA treated rats revealed a strong perivascular edema, a marker of pulmonary endothelial damage. Finally, AA treatment was accompanied by a severe metabolic shift toward glycolysis, a hallmark of PAH pathology. Conclusions: Chronic mitochondrial dysfunction induces the combination of vascular damage and metabolic reprogramming that may be responsible for PAH development. This mechanism may be especially important in females, perhaps due to an increased NO production and nitrosative stress development.Note
Open Access Journal.ISSN
1465-993XPubMed ID
29685148Version
Final published versionSponsors
NIH [1R01HL133085, R01HL136603, 1R01HL132918, 14SDG20480354]ae974a485f413a2113503eed53cd6c53
10.1186/s12931-018-0776-1
Scopus Count
Collections
Except where otherwise noted, this item's license is described as © The Author(s). 2018. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License.
Related articles
- Increased in vivo mitochondrial oxygenation with right ventricular failure induced by pulmonary arterial hypertension: mitochondrial inhibition as driver of cardiac failure?
- Authors: Balestra GM, Mik EG, Eerbeek O, Specht PA, van der Laarse WJ, Zuurbier CJ
- Issue date: 2015 Feb 3
- Ischemia-induced Drp1 and Fis1-mediated mitochondrial fission and right ventricular dysfunction in pulmonary hypertension.
- Authors: Tian L, Neuber-Hess M, Mewburn J, Dasgupta A, Dunham-Snary K, Wu D, Chen KH, Hong Z, Sharp WW, Kutty S, Archer SL
- Issue date: 2017 Apr
- Combination therapy improves vascular volume in female rats with pulmonary hypertension.
- Authors: Lachant DJ, Meoli DF, Haight D, Staicu S, Akers S, Glickman S, Ambrosini R, Champion HC, White RJ
- Issue date: 2019 Oct 1
- Novel assessment of haemodynamic kinetics with acute exercise in a rat model of pulmonary arterial hypertension.
- Authors: Brown MB, Chingombe TJ, Zinn AB, Reddy JG, Novack RA, Cooney SA, Fisher AJ, Presson RG, Lahm T, Petrache I
- Issue date: 2015 Jun
- Allogenic stem cell therapy improves right ventricular function by improving lung pathology in rats with pulmonary hypertension.
- Authors: Umar S, de Visser YP, Steendijk P, Schutte CI, Laghmani el H, Wagenaar GT, Bax WH, Mantikou E, Pijnappels DA, Atsma DE, Schalij MJ, van der Wall EE, van der Laarse A
- Issue date: 2009 Nov